Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL6387852 | 0.98 | CHRM2 (0.33) | CHRM2HRH3ACHECHRM4CHRM5 | |
| Formamide SCHEMBL4415470 | 0.96 | HPGD (0.35) | CHRM2 | |
| Formamide SCHEMBL6390884 | 0.94 | GAA (0.34) | — | |
| Formamide SCHEMBL14779600 | 0.85 | — | — | |
| SCHEMBL88667 | 0.84 | — | — | |
| SCHEMBL11014798 | 0.84 | — | — | |
| SCHEMBL292798 | 0.84 | — | — | |
| SCHEMBL254419 | 0.84 | — | — | |
| Ammonia Solution, Strong SCHEMBL1561055 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL5763760 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117693507-A | Inhibitor compounds | 奈奥芬莱有限公司 | 2024-03-12 | — | — | CN | claimed |
| CN-116583283-A | CDK inhibitors and their use as pharmaceuticals | 普莱鲁德疗法有限公司 | 2023-08-11 | — | — | CN | claimed |
| CN-115611924-A | PD-1/PD-L1 inhibitor and preparation method and application thereof | 上海华汇拓医药科技有限公司 | 2023-01-17 | — | — | CN | claimed |
| CN-111051295-B | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2022-09-02 | — | — | CN | claimed |
| CN-109311860-B | Xanthone derivatives for the treatment or prevention of hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2022-04-08 | — | — | CN | claimed |
| CN-113365696-A | Pharmaceutical compounds and their use as inhibitors of ubiquitin-specific protease 19(USP19) | 阿尔麦克探索有限公司 | 2021-09-07 | — | — | CN | claimed |
| CN-106573915-B | Compounds active against bromodomains | 纽韦卢森公司 | 2020-12-25 | — | — | CN | claimed |
| CN-112135818-A | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin-specific protease 19(USP19) | 阿尔麦克探索有限公司 | 2020-12-25 | — | — | CN | claimed |
| CN-111051295-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2020-04-21 | — | — | CN | claimed |
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2020-03-05 | — | — | US | claimed |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2017-09-14 | — | — | US | claimed |
| CN-101466710-B | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC | 2013-05-29 | — | — | CN | claimed |
| CN-101466710-A | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2009-06-24 | — | — | CN | claimed |
| CN-118344346-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-16 | — | — | CN | disclosed |
| CN-118339156-A | 2-Diazo-3-oxo-2, 3-dihydrospiro [ indene-1, 9' -xanthene ] derivatives and similar compounds as photoactive fluorescent compounds for protein labelling | 爱康治疗公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118290408-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-05 | — | — | CN | disclosed |
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | disclosed |
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB | 2006-11-16 | — | — | US | disclosed |
| EP-1450808-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | TPD52L2, NQO2, H1-5 | CHRM2 164/4885HRH3 439/4885ACHE 1688/4885 |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | CHRM2 284/4885HRH3 180/4885ACHE 1346/4885 |
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | CHRM2 284/4885HRH3 180/4885ACHE 1346/4885 |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | NQO2, TOP1, TPD52L2 | CHRM2 260/4885HRH3 666/4885ACHE 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.